器官移植技术公司TransMedics Group Inc.（股票代码：TMDX）在发布强劲的第二季度财报后，股价在夜盘交易中大涨14.20%，引起了投资者的广泛关注。该公司的业绩远超华尔街分析师预期，并且上调了全年收入指引，展现了强劲的增长势头。
根据公司发布的财报，TransMedics第二季度调整后每股收益达到0.92美元，是分析师平均预期0.45美元的两倍多。公司营收同比增长37.7%，达到1.5737亿美元，同样超过了分析师预期的1.4786亿美元。这一亮眼业绩表明公司的OCS和NOP平台在移植市场上的竞争力不断增强。
除了强劲的季度业绩外，TransMedics还上调了2025财年的全年营收指引至5.85亿美元至6.05亿美元，较此前预测有显著提升。公司还宣布获得FDA有条件的研究设备豁免批准，可以启动Next-Gen OCS™肺部试验，这进一步增强了投资者对公司未来发展前景的信心。TransMedics保持了61%的高毛利率，净利润达到3490万美元，占营收的22%，显示出公司良好的盈利能力和运营效率。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.